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BACKGROUND AND PURPOSE
Bortezomib (Velcade®) is a breakthrough treatment for multiple myeloma, signiﬁcantly improving patient survival. However, its
use is limited by painful neuropathy often resulting in dose reduction/cessation of ﬁrst-line treatment due to lack of treatment. The
aim of this study was to characterize a clinically relevant rat model of bortezomib-induced painful neuropathy, using established
evoked measures and novel ethological techniques, to aid drug discovery.
EXPERIMENTAL APPROACH
Adult male Sprague–Dawley rats were injected i.p. with 0.1 and 0.2 mg·kg1 bortezomib, or its vehicle, on days 0, 3, 7 and 10.
Multiple behavioural approaches were utilized: mechanical hypersensitivity, cold allodynia, heat hypersensitivity, motor co-
ordination, burrowing and voluntary wheel running. At maximal bortezomib-induced mechanical hypersensitivity, 200 mg·kg1
ethosuximide/vehicle and 100mg·kg1 phenyl N-tert-butylnitrone (PBN)/vehicle were administered i.p. in separate experiments,
and mechanical hypersensitivity assessed 1, 3 and 24 h later.
KEY RESULTS
Bortezomib induced dose-related mechanical hypersensitivity for up to 80 days. Bortezomib induced short-term cold allodynia,
but no signiﬁcant change in heat hypersensitivity, motor co-ordination, voluntary wheel running and burrowing behaviour
compared to vehicle-treated controls. Systemic PBN and ethosuximide signiﬁcantly ameliorated bortezomib-induced mechanical
hypersensitivity.
CONCLUSIONS AND IMPLICATIONS
These data characterize a reproducible rat model of clinical-grade bortezomib-induced neuropathy demonstrating long-lasting
pain behaviours to evoked stimuli. Inhibition by ethosuximide and PBN suggests involvement of calcium and/or ROS in
bortezomib-induced painful neuropathy. These drugs could be used as preclinical positive controls to assess novel analgesics. As
ethosuximide is widely used clinically, translation to the clinic to treat bortezomib-induced painful neuropathy may be possible.
Abbreviations
ATF3, activating transcription factor 3; BIPN, bortezomib-induced painful neuropathy; DRG, dorsal root ganglia; IENF,
intraepidermal nerve ﬁbre; PBN, phenyl-N-tert-butylnitrone
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Introduction
Bortezomib (Velcade®) is the ﬁrst of a new family of che-
motherapeutics known as proteasome inhibitors. Primarily,
bortezomib is a ﬁrst-line agent in treatment of newly diag-
nosed and relapsed multiple myeloma (Engelhardt et al.,
2010), with further trials showing effectiveness against
non-Hodgkin’s lymphoma (Bose et al., 2014) and solid carci-
nomas, including renal, prostate and ovarian tumours
(Cusack, 2003; Huang et al., 2014). Bortezomib is a boronic
acid dipeptide which reversibly binds and inhibits the 20S
catalytic subunit of the 26S proteasome (Adams, 2002). Pro-
teasome inhibition has been shown to interrupt critical cell
pathways, including the ubiquitin-proteasome pathway and
p53, JNK and NFκB activity, to induce apoptosis (Hideshima
et al., 2003; Voorhees et al., 2003). Malignant cells are more
sensitive to proteasome inhibition, undergoing apoptosis
more readily than healthy cells (reviewed in Voorhees et al.,
2003). Bortezomib can indirectly polymerise tubulin, causing
microtubule stabilization, axonal transport inhibition and
G2M phase cell cycle arrest (Poruchynsky et al., 2008; Rapino
et al., 2013; Staff et al., 2013).
Multiple studies report a high incidence (36–75%) of pe-
ripheral neuropathy following bortezomib administration
(reviewed in Argyriou et al., 2008; Badros et al., 2007;
Cavaletti and Jakubowiak, 2010; Seretny et al., 2014). The
high incidence of neuropathy occurs across patient groups,
whether newly diagnosed or relapsed/progression multiple
myeloma (52 vs. 55%, respectively; Corso et al., 2010). Previ-
ously untreated patients, who received bortezomib, have
shown less frequent neuropathic pain which rapidly
improved, compared to relapsed patients treated with
bortezomib. However, sensory symptoms, including paraes-
thesia and dysesthesia, persisted signiﬁcantly longer in previ-
ously untreated patients (Corso et al., 2010). Multicentre
phase 2 and phase 3 studies have shown that up to 75% of pa-
tients with bortezomib-induced painful neuropathy (BIPN)
had resolution of symptoms within 2–3 months of treatment
cessation or dose-modiﬁcation (reviewed in Delforge et al.,
2010). However, 25% of BIPN patients remain unaffected by
dose alteration and have their quality of life adversely
affected for long periods (13–20months) following treatment
(13–20 months; Corso et al., 2010; Richardson et al., 2006;
Richardson et al., 2009). BIPN is characterized by painful
paraesthesia, hypoesthesia, cold allodynia and heat
hypersensitivity with little motor impairment reported (Cata
et al., 2007; Argyriou et al., 2008; Cavaletti and Jakubowiak,
2010). Currently, there are no effective treatments for
bortezomib-induced peripheral neuropathy. At present, dose-
reduction and change in dosing regimen/administration is
recommended to limit establishment of BIPN (Moreau et al.,
2011; 2012; Argyriou et al., 2014).
A number of animal models of BIPN exist in both mice
and rats, recently reviewed by Hopkins et al. (2016). In this
study, Velcade® was administered at regular intervals to
mimic the ﬁrst bortezomib treatment cycle. The ﬁrst aim of
this investigation was to comprehensively characterize a rat
model of BIPN using several behavioural techniques,
encompassing both established measures to evoked pain
stimuli and novel ethological activity measures. These tech-
niques were used to investigate patient-reported symptoms,
whilst using clinically relevant dosage, cycle regimen and
grade of bortezomib. The second aim of this study was to
assess if novel analgesics shown to be effective in a rat model
of paclitaxel-induced painful neuropathy were also effective
in this model. This was done to identify potential positive
controls and mechanistic insight for the assessment of
novel-analgesics against BIPN.
Methods
Animals
Adult male Sprague–Dawley rats (180–200 g; Envigo) were
housed in cages of four to ﬁve, in a climate-controlled envi-
ronment with a 12 h light/dark cycle. Animals had free access
to food and water, and all cages contained sawdust and envi-
ronmental enrichment materials. Animal studies are reported
in compliance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath and Lilley, 2015). All procedures were con-
ducted in strict accordance with the UK Animals (Scientiﬁc
Procedures) Act, 1986, and the IASP ethical guidelines
(Zimmerman, 1983). Protocols used were approved by the
Ethics Review Panel of King’s College London and conducted
under the UK Home Ofﬁce project licence 70/8015.
Drug administration
Velcade®, clinical grade bortezomib (Millennium Pharma-
ceuticals Inc., Takeda Pharmaceutical Company Limited),
was used to induce bortezomib-induced peripheral neuropa-
thy. Powdered Velcade® was reconstituted with 0.9% sterile
saline (Fresenius Kabi, UK) to achieve a solution with a ﬁ-
nal concentration of 0.2 mg·mL1. A vehicle solution of
0.2 mg·mL1 D-mannitol (Sigma, UK), in 0.9% sterile sa-
line, was used to replicate clinical Velcade®. Animals re-
ceived 0.1 or 0.2 mg·kg1 bortezomib i.p. or an equal
volume of vehicle solution on days 0, 3, 7 and 10. Dosage
and administration schedule was based on clinical use of
Velcade® [1.3 mg·m2 (Conversion factor: Nair and Jacob,
2016) on days 0, 3, 7 and 10 (Moreau et al., 2012)].
Velcade® has been shown to induce dose-dependent pro-
teasome inhibition, with a single dose of 1.38 mg·m2
yielding 74 ± 2% inhibition, which returned towards base-
line after 72 h (More detail: Orlowski et al., 2002).
Mechanical hypersensitivity
As described previously (Grifﬁths and Flatters, 2015; Duggett
et al., 2016), animals were habituated to the testing environ-
ment two to three times on separate days prior to assessment
of baseline mechanical responses. The testing environment
consisted of an elevated Perspex box with a wire-rung ﬂoor,
with clear dividers creating 15 × 16 × 21 cm boxes for each an-
imal. Withdrawal responses to von Frey ﬁlaments of 4, 8 and
15 g bending force (Touch-Test™ Sensory Evaluators, Linton
Instrumentation, UK) were used to assess mechanical hyper-
sensitivity as described previously (Grifﬁths and Flatters,
2015), with scores from both hind paws added together to
give a maximum possible score of 10 for each bending force
ﬁlament weight. In brief, each ﬁlament was applied ﬁve
times, for 5 s, to the midplantar region of the hind paw. All
animals were tested using one von Frey ﬁlament on one hind
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paw before beginning to test the other hind paw with the
same bending force ﬁlament. Three baseline measurements,
taken on separate days, were recorded prior to administration
of bortezomib/vehicle, and von Frey withdrawal responses to
all bending forces were then measured at 1–2 week intervals
in order to fully characterize the time course of bortezomib-
induced mechanical hypersensitivity, n = 7 per group.
Mechanical hypersensitivity was assessed between 08:00
and 11:00 h on all occasions.
Cold allodynia
The testing environment for cold hypersensitivity testing was
the same as that described above for mechanical hypersensi-
tivity and was assessed as detailed previously (Fidanboylu
et al., 2011). In brief, 50 μL of acetone (Sigma, UK) was applied
to the plantar surface of each hind paw and a stopwatch
started. Responses were scored as follows: 0, no response; 1,
a single response (lifting, ﬂicking or stamping the paw); 2,
multiple/prolonged responses; 3, repeated responses and
licking of the plantar surface. Responses were graded initially
over the ﬁrst 20 s following acetone application. A score of
zero was given if the animal did not respond in the ﬁrst 20 s
following application. If the animal did respond within this
time frame, the animal’s response was assessed for an
additional 20 s. Each hind paw was tested three times, giving
a total score out of 18 for each animal. Hind paw testing was
non-consecutive, with each animal tested on one hind paw
before returning to the original animal to test the same hind
paw again, n = 7 per group. The minimum time between
acetone applications to the same hind paw was 8 min. Cold
allodynia was tested on days 0, 6, 11, 14, 18, 21, 26, 33, 42,
48, 54, 61 and 74.
Thermal hyperalgesia
Heat hyperalgesia was assessed using an infrared heat source
(Ugo-Basile, Italy). An infrared beam was targeted to the
plantar heel surface of each hind paw, which automatically
cuts off when paw was withdrawn. The latency from initia-
tion of stimulation to paw withdrawal was displayed and
recorded. Withdrawal latency was assessed for each hind
paw in turn, three times in a non-consecutive manner to
avoid sensitization. For example, each animal had their left
hind paw tested once, before the ﬁrst animal was tested a
second time on the left paw. The average time between heat
stimulation to the same hind paw was 6 min. Latencies for
each hind paw were added together and averaged to give
the mean of all six measurements, n = 8 per group. The
infrared intensity was maintained at 150–160 mW·cm3 as
measured using a Heat Flux Radiometer (Ugo-Basile, Italy).
Thermal hyperalgesia was assessed on days 0, 5, 11, 14, 18,
21, 28, 35, 46 and 63.
Motor co-ordination
Motor performance was assessed using an accelerating
Rota-rod (Ugo-Basile, Italy). Animals were positioned on the
rota-rod at an initial speed of 4 rpm, with speed increasing
40 rpm over 300 s; the latency for the rat to fall onto the sen-
sor platform was recorded. Animals were habituated to the
rota-rod on three separate occasions and were required to sus-
tain movement on the rota-rod for a minimum of 60 s on two
of these occasions in order to be included in the study. Two
baseline assessments were conducted for each animal on dif-
ferent days, with one trial conducted per time point assessed,
n = 8 per group. Motor coordination was assessed on days 0, 5,
11, 19, 26, 33, 46 and 60.
Burrowing behaviour
Burrowing behaviour was assessed using custom-made
burrowing tubes in a protocol based on work previously de-
scribed (Deacon, 2006; Andrews et al., 2012; Huang et al.,
2013). Burrowing tubes were 32 cm in length, 10 cm in diam-
eter, and had one end sealed. The open end was raised by ap-
proximately 6 cm. Animals were housed in pairs and
habituated to empty burrowing tubes in their home cage for
a minimum of 24 h. Following this, training was initiated.
Training sessions consisted of the cage mates being moved
to a fresh home-cage which contained the burrowing tube,
which they had been habituated to, ﬁlled with 2500 g of
5 mm shingle (Porton Garden, Aquatics and Pets Centre,
UK) and a disposable inco pad (Guy’s Hospital) in lieu of saw-
dust. Animals were trained in pairs for 2 h, from 16:00 to
18:00 h, after which they were returned to their original
home cage with sawdust and environmental enrichment ma-
terials, without the burrowing tube. This was repeated on two
consecutive days, if any pairs of animals did not burrow in
the ﬁrst training session the pairings were swapped with
animals that did show burrowing activity. Animals had free
access to food and water at all times.
Following training, a baseline burrowing measurement
was taken the following day. Animals were individually
housed with a burrowing tube containing 2500 g 5 mm shin-
gle and an inco pad from 16:00 to 18:00 h. After this time, an-
imals were returned to their home-cage and respective cage
mate. The quantity of gravel dislodged and latency to start
burrowing were recorded, and the weight of gravel dislodged
was used to group-match the animals prior to drug adminis-
tration, to ensure similar baseline burrowing behaviour be-
tween treatment groups, n = 6 vehicle, n = 7 bortezomib.
Animals were individually placed in the burrowing set-up
from 16:00 to 18:00 h on day 4, day 19 and day 33 post-initial
bortezomib/vehicle administration with latency and quan-
tity of gravel displaced recorded at each time point. Other
than during the training period, animals were exposed to
the same burrow and gravel and were returned to the same
home cage and cage mate for the duration of the study.
Voluntary wheel running
Spontaneous activity was assessed using Activity Wheels,
model, BIO-ACTIVW-R (Bioseb, Boulogne, France). This soft-
ware allowed recording of activity within a cage similar to
that of the animal’s home cage, with overall dimensions of
48 × 31.5 × 47 cm and wheel dimension of 34 cm height,
7 cm width. Cages were Type III polycarbonate, and wheels
were made of stainless steel. Animals had access to food and
water ad libitum and free access to the wheel. Activity wheel
cages contained sawdust only and were kept within the room
that the rats were normally housed. Animals were individu-
ally housed in activity wheel cages during recording periods,
after which they were returned to their home cage and cage
mates. The activity wheels were connected to a computer
and ActivWheel software which automatically recorded a
number of parameters: active time, distance travelled, speed,
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acceleration and access count, throughout the recording pe-
riod. Animals were habituated to the activity wheel cage for
1 h during the day prior to overnight recordings. As rodents
are nocturnal and previous studies have shown that the ma-
jority of wheel running occurs during the dark cycle
(Eikelboom and Mills, 1988), this period was focussed upon
during this investigation. For baseline recordings (day 0), an-
imals were placed in the activity wheel cage at 18:00 h, until
09:00 h the following day. Animals were split into two groups
based on the total distances travelled at baseline recorded
during the dark cycle. Animals were placed in their activity
wheel cage again on day 4, day 19 and day 33, for 1 h during
the light cycle to habituate and then from 18:00 to 09:00 h
the following day. Data graphed in Figure 7 were obtained
during the dark cycle, 19:30 to 06:30 h (avoiding the
dusk/dawn phase). Animals were always exposed to the same
activity wheel cage and returned to the same home cage and
cage mates, n = 12 per group.
Histological analyses
In order to investigate whether bortezomib administration
induced neuronal damage, several parameters were investi-
gated. Axon myelination was investigated using osmium
staining conducted by Carl Hobbs; at day 24, sciatic nerve
samples were taken from bortezomib and vehicle-treated ani-
mals. Samples were incubated for 24 h in 10% formalin, before
being washed with distilled water three times, and incubation
with 0.1% osmium for 2 h at room temperature (RT). Tissue
specimens were washed with distilled water for 15 min three
times, before being embedded in parafﬁn wax. Cross-sectional
nerve sections were cut at 8 μm, mounted and air-dried. Slides
were incubated at 62°C for 2 h before dehydrating with xylene
for 10 min and coverslipping with DPX. Slides were
randomized and regions selected to count axons highlighted
by S.J.L.F. Axons that did not have a clear lumen or suggested
compromised myelin were not included in the assessment.
The experimenter was blind throughout analyses. Sample size
was based on number of animals, n = 5 per group.
Additionally, activating transcription factor 3 (ATF3) im-
munoﬂuorescence was conducted on 16 μm L5 dorsal root
ganglion (DRG) sections cut onto slides from bortezomib
and vehicle-treated animals at day 24, peak mechanical hy-
persensitivity. Anti-ATF3 primary antibody (1:500, O/N at
4°C, Santa-Cruz Biotechnology, USA) was used, followed by
goat anti-rabbit CY3 secondary antibody (1:400, 90 min at
RT, Jackson ImmunoResearch Laboratories Inc., USA) using
the methodology previously described (Flatters, 2008). Non-
sequential sections were analysed with total cell counts taken
from three sections per animal. Sample size was based on
number of animals, (n = 6 per group).
Intraepidermal nerve ﬁbres (IENFs) were analysed in the
hind paw skin of bortezomib and vehicle-treated animals at
day 24. Hind paw skin was sectioned onto slides at 10 μM
and hydrated for 10 min in PBS. Sections were then blocked
for 1 h at RT in a diluent solution (1% BSA, 0.1% Triton in
PBS). Slides were incubated with pan-neuronal marker pro-
tein gene product 9.5 (anti-PGP 9.5, 1:5000, Ultraclone Ltd,
UK) overnight in diluent solution at RT. Slides were then
washed three times for 10 min in PBS before incubation with
goat anti-rabbit Cy3 (1:500, Jackson ImmunoResearch Labo-
ratories Inc., USA) in diluent for 90 min at RT. Slides were
washed three times for 10 min in PBS, before being
coverslipped using Vectashield with DAPI to identify the
dermal-epidermal border. Scoring criteria were based on
guidelines recommended by the European Federation of Neu-
rological Societies (Lauria et al., 2005). For each animal, 32
images of skin IENFs were analysed. Images were taken from
four ﬁelds of view per skin section, with eight non-sequential
sections analysed per animal under blind conditions. Sample
size was based on number of animals (n = 6 per group).
Drug treatment studies on established
bortezomib-induced mechanical
hypersensitivity
On day 21 post initial injection of bortezomib, mechanical
hypersensitivity to von Frey ﬁlaments was assessed (n = 14)
as detailed above. Animals were split into two groups that
displayed similar levels of mechanical hypersensitivity to 4,
8 and 15 g von Frey stimulation. Animals received
200 mg·kg1 ethosuximide (dissolved in saline, Sigma,
UK, n = 7) or saline (n = 7), administered i.p. All animal’s me-
chanical hypersensitivity was then tested 1, 3 and 24 h after
ethosuximide/vehicle administration.
At day 24 post initial administration of bortezomib, me-
chanical hypersensitivity to 4, 8 and 15 g von Frey ﬁlaments
was assessed. Animals were split into matched groups
based on their responses to von Frey stimulation. A total
of 100 mg·kg1 of reactive oxygen scavenger, phenyl-N-
tert-butylnitrone (PBN), dissolved in saline (Sigma, UK;
n = 7) or saline (n = 7) were administered i.p. Mechanical
hypersensitivity was assessed 1, 3 and 24 h after
PBN/vehicle administration. Dosing for ethosuximide and
PBN was based on previous studies (Flatters and Bennett,
2004; Fidanboylu et al., 2011).
Blinding and randomization
All behavioural testing was carried out by a single
experimenter (N.A.D.), who was blind to the treatment
group. For drug (PBN and ethosuximide) studies on
established mechanical hypersensitivity, randomization of
animals and all injections were performed by a different ex-
perimenter (S.J.L.F.). Animals were allocated to experimental
groups based on their baseline responses to the respective
behavioural test. In order to reduce the effect of extraneous
variables on behavioural assessment, concurrent vehicle-
treated groups were present throughout all experiments. All
bortezomib/vehicle injections were administered in the early
afternoon 13:00 to 15:00 h, and ethosuximide/PBN/vehicle
injections were administered between 11:00 and 12:00 h.
All behaviour and drug administrations were conducted in
designated procedure facilities within the King’s College
London Biological Services Unit. Behavioural testing was
conducted in the morning, between 08:00 and11:00 h.
Statistical analysis
All statistical analyses were carried out on raw data using
GraphPad Prism 6 or IBM SPSS Statistics 23. To monitor
weight gain in vehicle-treated compared to bortezomib-
treated rats, a two-way repeated measures ANOVA with
Holm-Sidak post hoc test was conducted. Mechanical hyper-
sensitivity time course data were analysed using a two-way
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ANOVA with Holm-Sidak post hoc test. The time course of
bortezomib-induced cold hypersensitivity was analysed
using Friedman test with Dunn’s post hoc compared to base-
line scores in each group. Heat hypersensitivity and motor
coordination, in conjunction with bortezomib administra-
tion, were analysed using repeated measures two-way
ANOVA with Holm-Sidak post hoc test. Spontaneous
burrowing activity in bortezomib- and vehicle-treated ani-
mals was analysed using repeated measures two-way ANOVA,
and one animal was removed from the vehicle group as it
failed to burrow at day 33. Voluntary wheel running behav-
iour in conjunction with bortezomib/vehicle administration
was analysed using repeated measures two-way ANCOVA,
using baseline values as the covariate. Pairwise analysis was
also conducted in SPSS, with Bonferroni adjustment. The ef-
fect of ethosuximide and PBN on established bortezomib-
induced mechanical hypersensitivity was analysed using un-
paired two-tailed t-tests, with pre- and post bortezomib data
compared using paired one-tailed t-tests. Statistical signiﬁ-
cance was accepted at P < 0.05, with no further distinction
made for P < 0.01. The data and statistical analysis comply
with the recommendations on experimental design and anal-
ysis in pharmacology (Curtis et al., 2015).
Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding
entries in http://www.guidetopharmacology.org, the common
portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Southan et al., 2016).
Results
All rats appeared healthy throughout the studies.
Bortezomib- and vehicle-treated animals gained weight
throughout the investigation, and there was no signiﬁcant
difference between the groups throughout the time course
of the study (Figure 1, n = 8, repeated measures two-way
ANOVA with Holm-Sidak post hoc test). Bortezomib-treated
animals showed no signed of alopecia or diarrhoea, using ei-
ther dosing regimen.
Figure 2 shows that administration of bortezomib resulted
in a signiﬁcant and long-lasting mechanical hypersensitivity.
Following four systemic injections of 0.1 or 0.2 mg·kg1
bortezomib (cumulative dosing of 0.4 and 0.8 mg·kg1, re-
spectively) on days 0, 3, 7 and 10, there was a short delay be-
fore the onset of mechanical hypersensitivity. On day 14, a
Figure 1
Weight gain in bortezomib-treated and vehicle-treated animals.
Graph shows the mean ± SEM weight in g of rats, up to day 116, ex-
posed to bortezomib or its vehicle. Arrows indicate four injections of
0.2 mg·kg1 bortezomib or equivalent volume of vehicle on days 0,
3, 7 and 10. n = 8 per group.
Figure 2
Time course of mechanical hypersensitivity induced by bortezomib
(BTZ). (A–C) The mean ± SEM of the number of withdrawal re-
sponses to 4, 8 and 15 g von Frey, respectively, throughout the time
course. Arrows indicate four injections of 0.1 or 0.2 mg·kg1
bortezomib or equivalent volume of vehicle solution on days 0, 3, 7
and 10. *P < 0.05, vehicle versus 0.2 mg·kg1 bortezomib;
#P < 0.05, vehicle versus 0.1 mg·kg1 bortezomib; ¤P < 0.05,
0.1 mg·kg1 versus 0.2 mg·kg1 bortezomib. n = 7 per group.
Rat model of bortezomib-induced painful neuropathy BJP
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clear and signiﬁcant increase in mechanical hypersensitivity
was evident following both dosing regimens. A dose-related
difference in response duration was evident following
intermittent bortezomib administration; 0.1 mg·kg1
bortezomib-induced mechanical hypersensitivity lasted be-
tween 28 (4 and 8 g von Frey) and 52 days (15 g von Frey),
whereas 0.2 mg·kg1 bortezomib induced mechanical hyper-
sensitivity that lasted between 52 (4 and 8 g von Frey) and
80 days (15 g von Frey), when compared to concurrent
vehicle-treated controls. The mechanical hypersensitivity to
bortezomib also showed signiﬁcant dose-dependent effects
with 0.2 mg·kg1 resulting in signiﬁcantly greater mechani-
cal hypersensitivity than dosing at 0.1 mg·kg1. This was ev-
ident at days 18, 21 and 52 when stimulating at 4 g, at days
14–21, 52 and 80 when stimulating at 8 g, and at days
18–52 and 80 when stimulating at von Frey 15 g. Mechanical
hypersensitivity was deemed to have fully resolved after re-
sponses returned to individual baseline responses on two sep-
arate occasions (approximately 110 days after initial
bortezomib administration; n = 7 per group, two-way re-
peated measures ANOVA with Holm-Sidak post hoc test). We
have reproduced this time course of mechanical hypersensi-
tivity in three separate cohorts over the course of a year
(n = 12 per condition, per cohort).
Bortezomib (dosing at 0.2 mg·kg1) was shown to induce
a signiﬁcant cold hypersensitivity at day 14, when compared
to baseline responses (see Figure 3). Vehicle-treated animals
showed no signiﬁcant change in cold hypersensitivity at
any time point investigated (Friedman test, Dunn’s post hoc
test comparing to baseline scores, n = 7). Cold hypersensitiv-
ity was monitored until concurrent mechanical hypersensi-
tivity was deemed to have resolved. From these data,
late-phase cold hypersensitivity was not observed.
No signiﬁcant difference was observed in the withdrawal
latency to heat stimulation in bortezomib (0.2 mg·kg1
dosing) and vehicle-treated animals at any time point investi-
gated (Figure 4, repeated measures two-way ANOVA with
Holm-Sidak post hoc test, n = 8 per group). Points of elevated
withdrawal threshold, observed at days 21 and 35 in both
groups, were due to air conditioning in the testing room
lowering the ambient temperature and cooling of the glass
testing platform. Withdrawal latency was assessed up to day
63 following initial bortezomib/vehicle administration,
following the time course during which of mechanical
hypersensitivity emerges, no late-phase heat hypersensitivity
was observed.
Administration of four doses of 0.2 mg·kg1 bortezomib
on days 0, 3, 7 and 10 had no signiﬁcant effect on motor co-
ordination, assessed by the animal’s latency to fall from the
rota-rod, when compared to the latency of vehicle-treated
control animals (Figure 5, repeated measures two-way
ANOVAwith Holm-Sidak post hoc test, n = 8 per group). Motor
coordination was assessed up to day 60 following initial
bortezomib/vehicle administration, following the time
course during which of mechanical hypersensitivity becomes
established.
As shown in Figure 6, intermittent administration of
bortezomib (0.2 mg·kg1 dosing) had no signiﬁcant effect
on burrowing behaviour when compared to that of vehicle-
treated animals at any time point investigated. Burrowing
behaviour, amount of gravel displaced and latency to burrow
were investigated at day 4, day 19 and day 33 post initial
systemic administration of bortezomib/vehicle solution
(repeated measures two-way ANOVA with Holm-Sidak post
hoc test, n = 6 for vehicle, n = 7 for bortezomib). One animal
was removed from the vehicle group as it did not burrow
during the 2 h time period at day 33.
Voluntary wheel running, a novel ethological behav-
ioural test, was investigated in this study. Reported to be a
natural, elective behaviour and a stress-reduced method of
testing, we also found it to be a highly variable approach.
ANCOVA analysis identiﬁed that activity at baseline was a
Figure 3
Time course of bortezomib-induced cold hypersensitivity. Graph
shows the median ± interquartile range of the animal’s response to
acetone application throughout the time course of bortezomib-
induced mechanical hypersensitivity. Cold hypersensitivity was
evident at day 14 compared to baseline. Arrows indicate four
injections of 0.2 mg·kg1 bortezomib or equivalent volume of
vehicle on days 0, 3, 7 and 10. *P < 0.05, n = 7 per group.
NB. As this analysis is non-parametric, error bars appear larger
than expected from parametric analysis.
Figure 4
Effect of bortezomib administration on heat hypersensitivity.
Graph shows the mean ± SEM of the latency in seconds to with-
draw from a radiant heat stimulus. Arrows indicate four injections
of 0.2 mg·kg1 bortezomib or equivalent volume of vehicle, on
days 0, 3, 7 and 10, n = 8 per group.
BJP N A Duggett and S J L Flatters
6 British Journal of Pharmacology (2017) •• ••–••
signiﬁcant factor on data at later time points for all parame-
ters measured: total distance, active time, access count, mean
speed, maximal speed and maximal acceleration. The signiﬁ-
cance of an individual animal’s baseline activity was evident,
regardless of drug administration group. Therefore, two inde-
pendent cohorts of animals were exposed to this novel
behavioural approach and the data combined. Intermittent
administration of bortezomib (0.2 mg·kg1 dosing) was
shown to have a signiﬁcant effect on voluntary wheel run-
ning behaviour. Figure 7 shows that animals which received
bortezomib ran greater total distances, compared to vehicle-
treated controls (repeated measures –two-way ANCOVA with
baseline values, used as the covariate, n = 12 per group, two
separate cohorts n = 6 for both repeats). Although ANCOVA
analysis identiﬁed that bortezomib-treated animals ran sig-
niﬁcantly greater distances compared to vehicle-treated ani-
mals, pairwise analysis at individual time points did not
ﬁnd any signiﬁcant change in total distance run by
bortezomib-treated compared to vehicle-treated animals.
Bortezomib-treated animals also showed a trend towards in-
creased active time in the voluntary wheels, compared to
vehicle-treated controls (P < 0.1, repeated measures – two-
way ANCOVA with baseline values, used as the covariate,
n = 12 per group, two separate cohorts n = 6 for both repeats).
Although ANCOVA analysis identiﬁed that bortezomib-
treated animals ran signiﬁcantly greater distances compared
to vehicle-treated animals, pairwise analysis at individual
time points did not ﬁnd any signiﬁcant change in total dis-
tance run by bortezomib-treated compared to vehicle-treated
animals. All pairwise analyses were non-signiﬁcant, and these
analyses indicate the importance of accounting for individual
animal’s baseline activity in this novel assay.
The effect of a single systemic administration of
ethosuximide on bortezomib-induced mechanical hypersen-
sitivity is illustrated in Figure 8A–C. Signiﬁcant mechanical
Figure 5
Effect of bortezomib administration on motor coordination. The
graph shows the mean ± SEM of the latency in seconds, for vehicle-
and bortezomib-treated rats, to fall from an accelerating rota-rod.
Arrows indicate four injections of 0.2 mg·kg1 bortezomib or equiv-
alent volume of vehicle on days 0, 3, 7 and 10, n = 8 per group.
Figure 6
Spontaneous burrowing activity in bortezomib- and vehicle-treated animals. (A) Themean ± SEM of the weight of gravel displaced at baseline, day
4, day 19 and day 33 in the time course of bortezomib-inducedmechanical hypersensitivity. (B) The gravel displaced by an animal at day 4, 19 and
33 as a percentage of their respective weight of gravel displaced at baseline. (C) The mean ± SEM latency time to burrow in seconds at baseline,
day 4, day 19 and day 33. (D) The animal’s latency to initiate burrowing at day 4, 19 and 33 as a percentage of their respective latency to burrow
at baseline. n = 6 vehicle, n = 7 bortezomib.
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hypersensitivity was induced by day 21 following administra-
tion of 0.2 mg·kg1 bortezomib on days 0, 3, 7 and 10
(pre-bortezomib vs. post-bortezomib, *P < 0.05, paired one-
tailed t-tests) at all von Frey weights tested, as expected (see
Figure 2). One and 3 h post administration of 200 mg·kg1
ethosuximide bortezomib-induced mechanical hypersensi-
tivity was markedly inhibited to all von Frey stimulation
(Figure 8A–C, *P < 0.05, unpaired two-tailed t-tests). The
degree of mechanical hypersensitivity inhibition by
ethosuximide ranged from 41 to 60% across 4, 8 and 15 g
von Frey stimulation over 1 and 3 h time points. Twenty four
hours after administration, no signiﬁcant effect of
ethosuximide treatment was observed at 4 and 8 g von Frey
ﬁlaments when compared to vehicle-administrated
bortezomib-treated animals. However, at the 24 h time point
a small, but statistically signiﬁcant, analgesic effect of
ethosuximide administration was still evident at the 15 g
von Frey stimulation (Figure 8C, *P < 0.05, unpaired two-
tailed t-tests).
Figure 9A–C shows the effect of a single systemic dose of
the ROS scavenger, PBN, on established bortezomib-induced
mechanical hypersensitivity. Signiﬁcant mechanical hyper-
sensitivity was apparent at day 24 following administration
of 0.2 mg·kg1 bortezomib on days 0, 3 7 and 10 (Pre-
bortezomib vs. post-bortezomib, *P < 0.05, paired one-tailed
t-tests) with all von Freys examined. At 1 h following
100 mg·kg1 PBN administration, bortezomib-induced
mechanical hypersensitivity was inhibited at 15 g von Frey
ﬁlament testing only (Figure 9C,*P < 0.05 unpaired two-
tailed t-test). However, 3 h after PBN administration,
bortezomib-induced hypersensitivity was signiﬁcantly re-
duced at all von Frey weights tested, ranging from 20 to
52% inhibition (Figure 9A–C, *P < 0.05, unpaired two-tailed
t-tests). No effect of PBN on bortezomib-induced mechanical
hypersensitivity was observed 24 h after administration of
PBN at any von Frey stimulation.
We looked for evidence of neurodegeneration in several
ways. At peak mechanical hypersensitivity, day 24, axon
myelination, ATF3 staining (a known cell stress marker;
Tsujino et al., 2000) and IENFs were analysed. Bortezomib-
treated animals showed no signiﬁcant loss of axon
myelination, compared to vehicle-treated controls at day 24
(n = 5, vehicle 6.651 ± 0.66 axons mm2, bortezomib
7.815 ± 1.06 axons mm2). Additionally, no signiﬁcant differ-
ence in the quantity of ATF3-positive nuclei was found be-
tween bortezomib and vehicle-treated animals at day 24
(n = 6, vehicle 0.405 ± 0.18% + ve nuclei, bortezomib
0.408 ± 0.11% + ve nuclei). Also, IENF analysis did not iden-
tify a signiﬁcant difference in the number of nerve crossings
in the hind paw skin of vehicle and bortezomib-treated ani-
mals at day 24 (n = 6, vehicle 15.66 ± 1.48 IENF mm2,
bortezomib 17.35 ± 1.59 IENF mm2).
Figure 7
Effect of bortezomib administration on voluntary wheel running. (A) The active time animals spent in the wheel at baseline, day 4, day 20 and day
34 in the time course of bortezomib-induced mechanical hypersensitivity. (B) The total distance animals ran in the wheel at day 4, day 20 and day
34. (C) The access count of the wheel at day 4, day 20 and day 34. Results are presented as mean± SEM; n = 12 per group.
Figure 8
Effect of ethosuximide on established bortezomib-induced mechanical hypersensitivity. (A–C) The effect of systemic 200 mg·kg1 ethosuximide
or vehicle administration on behavioural responses to von Frey 4, 8 and 15 g stimulation, respectively, on day 21 following bortezomib
administration. Graphs show the mean ± SEM of response frequency to mechanical stimulation pre-bortezomib administration (Pre bortezomib),
after bortezomib but before ethosuximide/vehicle injection (Post bortezomib/Pre inj.), and then 1, 3 and 24 h following ethosuximide/vehicle
administration. *P < 0.05; n = 7 per group.
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Discussion
Here, we report a comprehensively characterized, transla-
tional rat model of BIPN, utilizing established evoked pain
measures and novel, ethological techniques. In conjunction
with development of this novel model, we found that
ethosuximide, an antiepileptic compound, successfully
inhibited bortezomib-induced mechanical hypersensitivity
for up to 24 h after administration, suggesting its potential
use as a positive control agent for testing novel analgesics.
In addition, we also ﬁnd that global inhibition of ROS,
through administration of PBN, can curb bortezomib-
induced mechanical hypersensitivity for several hours. We
have shown that a clear mechanical hypersensitivity de-
velops following bortezomib administration, evident in a
dose-related manner. Further dosing regimens were not in-
vestigated in this study as 0.2 mg·kg1 is equivalent to the
standard patient dosing at 1.3 mg·m2 (Argyriou et al.,
2014) and higher dosing has previously been shown not to
be tolerated in rats (Cavaletti et al., 2007).
Clinically, Velcade® is recommended for dosing at
1.3 mg·m2 on days 1, 4, 8 and 11 in a 21 day cycle in the ﬁrst
instance (Moreau et al., 2012). In patients, dosing with
Velcade® has been shown to induce a 60% loss of platelets,
which recovers over the 10 day rest period following dosing
(Lonial et al., 2005), and patients can develop thrombocyto-
penia and may require platelet transfusions. The schedule of
dosing followed in our investigation was designed to mimic
the intermittent dosing of one cycle of clinically adminis-
tered Velcade®. Many existing animal models administer
bortezomib at a dose higher than that recommended
clinically and/or over a longer period, not reﬂecting the rest
period included in the 21 day patient cycle. Additionally, dos-
ing at 0.3 mg·m2 i.v. was fatal to rats, and animals showed
distress and decreased weight gain following 0.2 mg·m2 i.v.
administration (Cavaletti et al., 2007). Thus, the pattern for
one bortezomib administration cycle was also followed here
to avoid animal health issues in accordance with the 3Rs prin-
ciples. We did not dose i.v., or for longer periods, to minimize
the impact on animal welfare, whilst reﬂecting the intermit-
tent nature of systemic Velcade® administration in patients.
Existing models of BIPN have also reported mechanical
hypersensitivity due to bortezomib dosing, but in a
shorter-lasting manner, 29 days (0.2 mg·kg1 bortezomib; Ya-
mamoto et al., 2015) and 54 days (0.2 mg·kg1 Velcade; Rob-
inson et al., 2014), compared to ~80 days in our investigation.
Dosing with bortezomib has also previously been shown to
induce cold allodynia at days 11 and 15 (Zheng et al., 2012;
Yamamoto et al., 2015), whereas Velcade® administration
was not associated with development of cold allodynia fol-
lowing four doses at 0.15 mg·kg1 (Robinson et al., 2014). In
conjunction with long-lasting mechanical hypersensitivity,
we found evidence of a short-lasting cold allodynia resulting
from four doses of 0.2 mg·kg1 Velcade®, evident at day 14
only. It is unlikely that long-lasting bortezomib-induced me-
chanical hypersensitivity and short-term cold allodynia are
due to impaired animal health or motor function as no
weight difference or alteration in rota-rod ability was evident
between groups. Collectively, these data suggest that drug for-
mulation, dose and dosing regimen are important factors in
developing models of BIPN.
Patients report painful paraesthesia, hypoesthesia, cold
allodynia, heat hypersensitivity and little motor impairment
(Cata et al., 2007; Argyriou et al., 2008; Cavaletti and
Jakubowiak, 2010), with a signiﬁcant proportion of patients
developing neuropathy after one treatment cycle
(Richardson et al., 2006; Broyl et al., 2010). The model in this
investigation closely mirrors the long-lasting nature of
bortezomib-induced mechanical pain in patients. Heat hyper-
sensitivity reported by patients (Cata et al., 2007) has not yet
been demonstrated in any rodent model of BIPN (see Hopkins
et al., 2016). We also did not observe heat hyperalgesia. One
mouse study reported heat hypoalgesia, although this may be
related to the high dosage used (Bruna et al., 2010). Our investi-
gation did not report anymotor impairment following rota-rod
assessment, and it was also absent in another study which uti-
lized Velcade® at a lower dose (0.15 mg·kg1; Robinson et al.,
2014). These studies correlate with the lack of motor impair-
ment observed in the human condition (Park et al., 2013).
Clinically, Velcade® is administered intravenously or sub-
cutaneously. Data have shown that subcutaneous administra-
tion results in an equivalent plasma level of bortezomib to
intravenous administration. Additionally, both administra-
tion routes displayed comparable proteasome inhibition
levels. The site of subcutaneous administration, thigh or ab-
domen, was also shown not to affect pharmacokinetic and
Figure 9
Effect of PBN on established bortezomib-induced mechanical hypersensitivity. (A–C) The effect of systemic 100 mg·kg1 PBN or vehicle admin-
istration on behavioural responses to von Frey 4, 8 and 15 g stimulation, respectively, on day 24 following bortezomib administration. Graphs
show the mean ± SEM of response frequency to mechanical stimulation pre-bortezomib administration (Pre bortezomib), after bortezomib but
before PBN/vehicle injection (Post bortezomib/Pre inj.), and then 1, 3 and 24 h following PBN/vehicle administration. *P < 0.05, n = 7 per group.
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pharmacodynamic parameters (Moreau et al., 2011; Moreau
et al., 2012). There does not appear to be an agreed consensus
regarding neuropathy incidence and administration routes,
with studies reporting contrasting results (Moreau et al.,
2011; Arnulf et al., 2012; Minarik et al., 2015), suggesting that
neuropathy prevalence is primarily linked to dosage. One an-
imal study has administered Velcade® subcutaneously
(Bruna et al., 2010); however, this study had a high cumula-
tive dose (12mg·kg1). The researchers state that this cumula-
tive dose is equivalent to patients’ receiving eight 21 day
cycles of Velcade®; however, animals were dosed over 6weeks
without the rest period included in the 21 day patient cycle.
This mouse model displays motor impairment, not been ob-
served in patients, as well as reduced myelinated sciatic ﬁbres
and a loss of IENFs in bortezomib-treated mice. The model
characterized in this study did not ﬁnd loss of motor function
or reduced axon myelination and IENF crossings in
bortezomib-treated animals compared to vehicle-treated con-
trols. Previous studies have identiﬁed degeneration of myelin-
ated sciatic nerve ﬁbres following the same dosing regimen
(albeit using non-Velcade® bortezomib) used in this study,
but an absence of ATF3-positive staining (Yamamoto et al.,
2015). Another investigation has reported, but did not quan-
tify, ATF3-positive staining in the DRG following bortezomib
administration following a signiﬁcantly higher cumulative
dose of 6.4 mg·kg1 (Carozzi et al., 2013). We did not observe
any signiﬁcant difference between the number of ATF3 positive
nuclei in the DRG of bortezomib- and vehicle-treated animals
at the peak mechanical hypersensitivity time point in this
study. Cavaletti et al. (2007) reported satellite cell vacuolization
in schwann cells of the DRG and damaged mitochondria but
only following cumulative dosing of 2.4 mg·kg1, with a num-
ber of lower dosing regimens, akin to the cumulative dose used
in thismodel, not causing these changes (Cavaletti et al., 2007).
Collectively, this suggests that neurodegeneration is associated
with higher doses of bortezomib.
Our investigation did not ﬁnd any change in burrowing
activity in this model of bortezomib-induced peripheral neu-
ropathy, when examined during the injection period or on
established mechanical hypersensitivity time points.
Burrowing is an innate, spontaneous activity displayed by
most rodents and is thought to be ethological, compared to
standard behavioural methods which examine responses to
evoked pain and thus reﬂect a better system to assess ongoing
pain and potential analgesics. Burrowing has been shown to
be sensitive to pharmacological treatments and induced con-
ditions, including peripheral nerve injury, joint inﬂamma-
tion and antiretroviral-associated neuropathy models
(Deacon, 2006; 2009; Andrews et al., 2012; Huang et al.,
2013; Rutten et al., 2014; Muralidharan et al., 2016; Wodarski
et al., 2016). This study found no difference in burrowing
activity in bortezomib-treated animals, compared to concur-
rent vehicle-treated controls at any time point investigated.
In contrast, paclitaxel administration impaired burrowing
activity (Grifﬁths et al., submitted). Although a large,
multicentre study has established a standard burrowing
protocol for CFA-induced inﬂammatory pain (Wodarski
et al., 2016), it may be that different pain models affect
burrowing behaviour in a diverse manner.
Voluntary wheel running, particularly in a home cage or
home cage-like environment, provides a stress-reduced
method of testing in which the animal can be monitored
objectively. Wheel running has been identiﬁed as a natural,
elective behaviour (Meijer and Robbers, 2014) and can be
assayed continuously or over a speciﬁc time period, for
instance, following administration of a potential novel
analgesic, without needing an experimenter to be present.
We found that bortezomib-treated animals, which showed
mechanical hypersensitivity at the same time points, ran at
greater distances when compared to concurrent vehicle-
treated animals over the time course examined. However,
pairwise analysis did not identify any signiﬁcant change in
total distance travelled by bortezomib-treated animals com-
pared to concurrent vehicle-treated controls. No other pa-
rameters (active time, access count, mean and maximum
speed and maximum acceleration) showed any signiﬁcant
differences between groups, and time point analyses were
all non-signiﬁcant. Wheel running has previously been
shown to be sensitive to a number of pain models, including
arthritis (Cobos et al., 2012; Kandasamy et al., 2016), osteoar-
thritis (Stevenson et al., 2011) and paclitaxel-induced periph-
eral neuropathy (Grifﬁths et al., submitted). The measures of
spontaneous behaviour used in the characterization of this
model of bortezomib-induced peripheral neuropathy have
not identiﬁed any signiﬁcant deﬁcits following administra-
tion of bortezomib. This is indicative of good health in the
animals; voluntary wheel running was conducted during
the night cycle, and burrowing was carried immediately prior
to the dark cycle initiating. Rats are nocturnal and have been
previously shown to be most active during the night cycle
(Eikelboom and Mills, 1988); in addition, minor motor
impairment has only been reported in a small number of
patients receiving Velcade® (Argyriou et al., 2008; Cavaletti
and Jakubowiak, 2010). Therefore, the absence of impaired
burrowing activity and voluntary wheel running behaviour
may be an accurate representation of the lack of motor im-
pairment reported by patients experiencing BIPN.
Currently, the only analgesic which is recommended for
treating existing chemotherapy-induced neuropathy,
namely, oxaliplatin-induced, is duloxetine (Hershman et al.,
2014; Majithia et al., 2016). A very small study has shown
duloxetine to be effective against BIPN in patients (Hirayama
et al., 2015); however, comprehensive clinical trials with
duloxetine and bortezomib-induced peripheral neuropathy
have yet to be conducted. A number of existing analgesics
have been tested in an animal model of bortezomib-induced
neuropathy (Yamamoto et al., 2015) and have been shown
to be effective in the short term, although themechanical hy-
persensitivity described in this model was signiﬁcantly
shorter in duration than that described in this investigation,
potentially not reﬂecting the patient experience of long-term
neuropathy following bortezomib administration. The
model described by Yamamoto et al. (2015) showed that ad-
ministration of tramadol, pregabalin, duloxetine and
mexiletine could ameliorate bortezomib-inducedmechanical
hypersensitivity, but only the effects of pregabalin exceeded
1 h (up to 3 h; Yamamoto et al., 2015). In our investigation,
administration of another calcium channel blocker,
ethosuximide, was shown to robustly inhibit bortezomib-
induced mechanical hypersensitivity at 1 and 3 h after a sin-
gle administration. Systemic administration of ethosuximide
has previously been shown to induce a dose-dependent
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reduction in mechanical hypersensitivity in a rat model of
paclitaxel-induced pain (Flatters and Bennett, 2004) and an-
algesic in rat models of traumatic nerve injury (Dogrul et al.,
2003; Hamidi et al., 2012; Goyal et al., 2015). There is also ev-
idence of calcium dysregulation in bortezomib-induced cell
death, with bortezomib causing transient intracellular ER
calcium release, resulting in mitochondrial-calcium inﬂux
and caspase activation (Landowski et al., 2005). This transient
release may alter the membrane potential of neurons and
induce spontaneous action potentials, propagating pain
signalling associated with bortezomib administration. In
conjunction with these data, Robinson et al. (2014) reported
that four systemic administrations of 0.15 mg·kg1 Velcade®
induced increased ﬁring and, long-lasting after discharge, of
spinal wide dynamic range neurons in rats with conﬁrmed
mechanical hypersensitivity (Robinson et al., 2014). Al-
though bortezomib is not known to cross the blood–brain
barrier, these ﬁndings suggest that the effect of bortezomib
administration on transient ER calcium release could involve
in the spread of altered membrane potentials across the PNS to
the CNS, leading to central sensitization as observed in other
pain models (Ji et al., 2003). Ethosuximide is a known T-type
calcium channel blocker; however, there is evidence that
ethosuximide can also inhibit persistent sodium and calcium-
activated potassium currents (reviewed: Rogawski and Loscher,
2004). Therefore, the effective inhibition of bortezomib-
induced mechanical hypersensitivity by ethosuximide may
not be through calcium channels alone. However, the potent
action of ethosuximide against bortezomib-induced mechani-
cal hypersensitivity in our study supports a role of calcium
dysregulation in the propagation of BIPN and emphasizes the
potential for ethosuximide as a positive control for the testing
of novel analgesics.
Bortezomib has also been shown to directly affect
mitochondria, causing accumulation of ubiquitinated
proteins within the mitochondrion, leading to a reduction
in mitochondrial membrane potential and increased reactive
oxygen production in vitro (Maharjan et al., 2014). This
provides evidence that in vivo ROS scavenging may be an
effective target in understanding and preventing BIPN.
Neuronally derived mitochondrial ROS have previously been
shown to have a signiﬁcant role in painful neuropathy associ-
ated with another chemotherapeutic, paclitaxel (Flatters and
Bennett, 2006; Fidanboylu et al., 2011; Grifﬁths and Flatters,
2015; Duggett et al., 2016). In conjunction with these data,
the global ROS scavenger, PBN, has been shown to ameliorate
paclitaxel-induced pain in the rat (Kim et al., 2010;
Fidanboylu et al., 2011). Systemic administration of PBN at a
time point where BIPN was established showed a signiﬁcant
reduction in mechanical hypersensitivity over 3 h after
dosing. Taken together, the reduction of BIPN-induced
mechanical hypersensitivity following administration of a
single dose of ethosuximide or PBN provides support for a
role for calcium and ROS in the potentiation of BIPN.
In summary, this study describes a translational rat model
of BIPN, induced by intermittent administration of clinical
formulation Velcade®, to mimic the ﬁrst bortezomib treat-
ment cycle. This model displays long-lasting dose-dependent
mechanical hypersensitivity and transient cold allodynia,
with no motor deﬁcits, reﬂecting symptoms typically
reported by patients. No effects of repeated bortezomib
administration were observed on novel ethological activity
measures. In addition, we have identiﬁed ethosuximide and
PBN as effective inhibitors of bortezomib-induced mechani-
cal hypersensitivity providing insight into the potential
mechanism of action through which BIPN develops. Further-
more, these drugs could be used as positive controls in the
assessment of novel analgesics in behavioural studies. Finally,
ethosuximide is a well-tolerated widely used treatment for
absence epilepsy and therefore may have therapeutic poten-
tial for the treatment of bortezomib-induced neuropathy in
patients.
Acknowledgements
These studies were funded by a British Pharmacological
Society (Integrative Pharmacology Fund) 2014 Pump
Priming Award. N.A.D. was supported by the Wellcome Trust
(WT093335A1A). Thanks to the following people for their
technical assistance in this work: the late, great Ann Pitcher for
construction of burrowing tubes; Carl Hobbs for sciatic nerve
staining/sectioning; Garry Fulcher for injections; and Brenda
Murage for a subset of the voluntary wheel-running
experiments.
Author contributions
S.J.L.F. conceived and designed the study. N.A.D. performed
experiments and data analysis. N.A.D. and S.J.L.F. wrote the
manuscript.
Conﬂict of interest
The authors declare no conﬂicts of interest.
Declaration of transparency and
scientiﬁc rigour
This Declaration acknowledges that this paper adheres to the
principles for transparent reporting and scientiﬁc rigour of
preclinical research recommended by funding agencies,
publishers and other organisations engaged with supporting
research.
References
Adams J (2002). Development of the proteasome inhibitor PS-341.
Oncologist 7: 9–16.
Andrews N, Legg E, Lisak D, Issop Y, Richardson D, Harper S et al.
(2012). Spontaneous burrowing behaviour in the rat is reduced by
peripheral nerve injury or inﬂammation associated pain. Eur J Pain
16: 485–495.
Argyriou AA, Iconomou G, Kalofonos HP (2008). Bortezomib-
induced peripheral neuropathy in multiple myeloma: a
comprehensive review of the literature. Blood 112: 1593–1599.
Rat model of bortezomib-induced painful neuropathy BJP
British Journal of Pharmacology (2017) •• ••–•• 11
Argyriou AA, Cavaletti G, Bruna J, Kyritsis AP, Kalofonos HP (2014).
Bortezomib-induced peripheral neurotoxicity: an update. Arch
Toxicol 88: 1669–1679.
Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de
Velde H et al. (2012). Updated survival analysis of a randomized phase
III study of subcutaneous versus intravenous bortezomib in patients
with relapsed multiple myeloma. Haematologica 97: 1925–1928.
Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP
et al. (2007). Neurotoxicity of bortezomib therapy in multiple
myeloma: a single-center experience and review of the literature.
Cancer 110: 1042–1049.
Bose P, Batalo MS, Holkova B, Grant S (2014). Bortezomib for the
treatment of non-Hodgkin’s lymphoma. Expert Opin Pharmacother
15: 2443–2459.
Broyl A, Corthals SL, Jongen JLM, van der Holt B, Kuiper R, de Knegt Y
et al. (2010). Mechanisms of peripheral neuropathy associated with
bortezomib and vincristine in patients with newly diagnosed
multiple myeloma: a prospective analysis of data from the HOVON-
65/GMMG-HD4 trial. Lancet Oncol 11: 1057–1065.
Bruna J, Udina E, Ale A, Vilches JJ, Vynckier A, Monbaliu J et al.
(2010). Neurophysiological, histological and immunohistochemical
characterization of bortezomib-induced neuropathy in mice. Exp
Neurol 223: 599–608.
Carozzi VA, Renn CL, Bardini M, Fazio G, Chiorazzi A, Meregalli C
et al. (2013). Bortezomib-induced painful peripheral neuropathy: an
electrophysiological, behavioral, morphological and mechanistic
study in the mouse. PLoS One 8: e72995.
Cata JP, Weng H-R, Burton AW, Villareal H, Giralt S, Dougherty PM
(2007). Quantitative sensory ﬁndings in patients with bortezomib-
induced pain. J Pain 8: 296–306.
Cavaletti G, Jakubowiak AJ (2010). Peripheral neuropathy during
bortezomib treatment of multiple myeloma: a review of recent
studies. Leuk Lymphoma 51: 1178–1187.
Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez
V, Ceresa C et al. (2007). Bortezomib-induced peripheral
neurotoxicity: a neurophysiological and pathological study in the
rat. Exp Neurol 204: 317–325.
Cobos EJ, Ghasemlou N, Araldi D, Segal D, Duong K,Woolf CJ (2012).
Inﬂammation-induced decrease in voluntary wheel running in mice:
a nonreﬂexive test for evaluating inﬂammatory pain and analgesia.
Pain 153: 876–884.
Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P,
Lazzarino M (2010). Bortezomib-induced peripheral neuropathy in
multiple myeloma: a comparison between previously treated and
untreated patients. Leuk Res 34: 471–474.
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz
MA et al. (2015). Experimental design and analysis and their
reporting: new guidance for publication in BJP. Br J Pharmacol 172:
3461–3471.
Cusack J (2003). Rationale for the treatment of solid tumors with the
proteasome inhibitor bortezomib. Cancer Treat Rev 29: 21–31.
Deacon RM (2006). Burrowing in rodents: a sensitive method for
detecting behavioral dysfunction. Nat Protoc 1: 118–121.
Deacon RMJ (2009). Burrowing: A sensitive behavioural assay, tested
in ﬁve species of laboratory rodents. Behav Brain Res 200: 128–133.
Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H
et al. (2010). Treatment-related peripheral neuropathy in multiple
myeloma: the challenge continues. Lancet Oncol 11: 1086–1095.
Dogrul A, Gardell LR, Ossipov MH, Tulunay CF, Lai J, Porreca F
(2003). Reversal of experimental neuropathic pain by T-type calcium
channel blockers. Pain 105: 159–168.
Duggett NA, Grifﬁths LA, McKenna OE, de Santis V,
Yongsanguanchai N, Mokori EB et al. (2016). Oxidative stress in the
development, maintenance and resolution of paclitaxel-induced
painful neuropathy. Neuroscience 333: 13–26.
Eikelboom R, Mills R (1988). A microanalysis of wheel running in
male and female rats. Physiol Behav 43: 625–630.
Engelhardt M, Kleber M, Udi J, Wasch R, Spencer A, Patriarca F et al.
(2010). Consensus statement from European experts on the
diagnosis, management, and treatment of multiple myeloma: from
standard therapy to novel approaches. Leuk Lymphoma 51:
1424–1443.
Fidanboylu M, Grifﬁths LA, Flatters SJL (2011). Global inhibition of
reactive oxygen species (ROS) inhibits paclitaxel-induced painful
peripheral neuropathy. PLoS One 6: e25212.
Flatters SJ, Bennett GJ (2004). Ethosuximide reverses paclitaxel- and
vincristine-induced painful peripheral neuropathy. Pain 109:
150–161.
Flatters SJ, Bennett GJ (2006). Studies of peripheral sensory nerves in
paclitaxel-induced painful peripheral neuropathy: evidence for
mitochondrial dysfunction. Pain 122: 245–257.
Flatters SJL (2008). Characterization of a model of persistent
postoperative pain evoked by skin/muscle incision and retraction
(SMIR). Pain 135: 119–130.
Goyal S, Singla S, Kumar D, Menaria G (2015). Comparison of the
effects of zonisamide, ethosuximide and pregabalin in the chronic
constriction injury induced neuropathic pain in rats. Ann Med
Health Sci Res 5: 189–196.
Grifﬁths LA, Flatters SJ (2015). Pharmacological modulation of the
mitochondrial electron transport chain in paclitaxel-induced painful
peripheral neuropathy. J Pain 16: 981–994.
Hamidi GA, Ramezani MH, Arani MN, Talaei SA, Mesdaghinia A,
Banafshe HR (2012). Ethosuximide reduces allodynia and
hyperalgesia and potentiates morphine effects in the chronic
constriction injury model of neuropathic pain. Eur J Pharmacol 674:
260–264.
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J,
Cavaletti G et al. (2014). Prevention and management of
chemotherapy-induced peripheral neuropathy in survivors of adult
cancers: American Society of Clinical Oncology clinical practice
guideline. J Clin Oncol 32: 1941–1967.
Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D,
Richardson P et al. (2003). Molecular mechanisms mediating
antimyeloma activity of proteasome inhibitor PS-341. Blood 101:
1530–1534.
Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K et al.
(2015). Effect of duloxetine in Japanese patients with chemotherapy-
induced peripheral neuropathy: a pilot randomized trial. Int J Clin
Oncol 20: 866–871.
Hopkins HL, Duggett NA, Flatters SJ (2016). Chemotherapy-induced
painful neuropathy: pain-like behaviours in rodent models and their
response to commonly used analgesics. Curr Opin Support Palliat
Care 10: 119–128.
Huang W, Calvo M, Karu K, Olausen HR, Bathgate G, Okuse K et al.
(2013). A clinically relevant rodent model of the HIV antiretroviral
drug stavudine induced painful peripheral neuropathy. Pain 154:
560–575.
BJP N A Duggett and S J L Flatters
12 British Journal of Pharmacology (2017) •• ••–••
Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Yet al. (2014). Efﬁcacy of
therapy with bortezomib in solid tumors: a review based on 32
clinical trials. Future Oncol 10: 1795–1807.
Ji RR, Kohno T, Moore KA,Woolf CJ (2003). Central sensitization and
LTP: do pain and memory share similar mechanisms? Trends
Neurosci 26: 696–705.
Kandasamy R, Calsbeek JJ, Morgan MM (2016). Home cage wheel
running is an objective and clinically relevant method to assess
inﬂammatory pain in male and female rats. J Neurosci Methods 263:
115–122.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010).
Animal research: reporting in vivo experiments: the ARRIVE
guidelines. Br J Pharmacol 160: 1577–1579.
Kim HK, Zhang YP, Gwak YS, Abdi S (2010). Phenyl N-tert-
butylnitrone, a free radical scavenger, reduces mechanical allodynia
in chemotherapy-induced neuropathic pain in rats. Anesthesiology
112: 432–439.
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT (2005).
Mitochondrial-mediated disregulation of Ca2+ is a critical
determinant of Velcade (PS-341/Bortezomib) cytotoxicity in
myeloma cell lines. Cancer Res 65: 3828–3836.
Lauria G, Cornblath DR, Johansson O, McArthur JC, Mellgren SI,
Nolano M et al. (2005). EFNS guidelines on the use of skin biopsy in
the diagnosis of peripheral neuropathy. Eur J Neurol 12: 747–758.
Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver
CR et al. (2005). Risk factors and kinetics of thrombocytopenia
associated with bortezomib for relapsed, refractory multiple
myeloma. Blood 106: 3777–3784.
Maharjan S, OkuM, Tsuda M, Hoseki J, Sakai Y (2014). Mitochondrial
impairment triggers cytosolic oxidative stress and cell death
following proteasome inhibition. Sci Rep 4: 5896.
Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL,
Loprinzi CL (2016). National Cancer Institute-supported
chemotherapy-induced peripheral neuropathy trials: outcomes and
lessons. Support Care Cancer 24: 1439–1447.
McGrath JC, Lilley E (2015). Implementing guidelines on reporting
research using animals (ARRIVE etc.): new requirements for
publication in BJP. Br J Pharmacol 172: 3189–3193.
Meijer JH, Robbers Y (2014). Wheel running in the wild. Proc Biol Sci
281: 1786.
Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I et al. (2015).
Subcutaneous bortezomib in multiple myeloma patients induces
similar therapeutic response rates as intravenous application but it
does not reduce the incidence of peripheral neuropathy. PLoS One
10: e0123866.
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X,
Grishunina M et al. (2011). Subcutaneous versus intravenous
administration of bortezomib in patients with relapsed multiple
myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol
12: 431–440.
Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska
KV, Doronin VA et al. (2012). Pharmacokinetic, pharmacodynamic
and covariate analysis of subcutaneous versus intravenous
administration of bortezomib in patients with relapsed multiple
myeloma. Clin Pharmacokinet 51: 823–829.
Muralidharan A, Kuo A, Jacob M, Lourdesamy JS, Carvalho LM,
Nicholson JR et al. (2016). Comparison of burrowing and stimuli-
evoked pain behaviors as end-points in rat models of inﬂammatory
pain and peripheral neuropathic pain. Front Behav Neurosci 10: 88.
Nair AB, Jacob S (2016). A simple practice guide for dose conversion
between animals and human. J Basic Clin Pharm 7: 27–31.
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS,
Stahl S et al. (2002). Phase I trial of the proteasome inhibitor PS-341 in
patients with refractory hematologic malignancies. J Clin Oncol 20:
4420–4427.
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J
et al. (2013). Chemotherapy-induced peripheral neurotoxicity: a
critical analysis. CA Cancer J Clin 63: 419–437.
Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C,
Fojo T (2008). Proteasome inhibitors increase tubulin polymerization
and stabilization in tissue culture cells: a possible mechanism
contributing to peripheral neuropathy and cellular toxicity following
proteasome inhibition. Cell Cycle 7: 940–949.
Rapino F, Naumann I, Fulda S (2013). Bortezomib antagonizes
microtubule-interfering drug-induced apoptosis by inhibiting G2/M
transition and MCL-1 degradation. Cell Death Dis 4: e925.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B,
Berenson J et al. (2006). Frequency, characteristics, and reversibility of
peripheral neuropathy during treatment of advanced multiple
myeloma with bortezomib. J Clin Oncol 24: 3113–3120.
Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T,
Harousseau JL et al. (2009). Reversibility of symptomatic peripheral
neuropathy with bortezomib in the phase III APEX trial in relapsed
multiple myeloma: impact of a dose-modiﬁcation guideline. Br J
Haematol 144: 895–903.
Robinson CR, Zhang H, Dougherty PM (2014). Altered discharges of
spinal neurons parallel the behavioral phenotype shown by rats with
bortezomib related chemotherapy induced peripheral neuropathy.
Brain Res 1574: 6–13.
Rogawski MA, Loscher W (2004). The neurobiology of antiepileptic
drugs. Nat Rev Neurosci 5: 553–564.
Rutten K, Schiene K, Robens A, Leipelt A, Pasqualon T, Read SJ et al.
(2014). Burrowing as a non-reﬂex behavioural readout for analgesic
action in a rat model of sub-chronic knee joint inﬂammation. Eur J
Pain 18: 204–212.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR
et al. (2014). Incidence, prevalence, and predictors of chemotherapy-
induced peripheral neuropathy: a systematic review and meta-
analysis. Pain 155: 2461–2470.
Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ,
Alexander SPH et al. (2016). The IUPHAR/BPS guide to
PHARMACOLOGY in 2016: towards curated quantitative
interactions between 1300 protein targets and 6000 ligands. Nucl
Acids Res 44: D1054–D1068.
Staff NP, Podratz JL, Grassner L, Bader M, Paz J, Knight AM et al.
(2013). Bortezomib alters microtubule polymerization and axonal
transport in rat dorsal root ganglion neurons. Neurotoxicology 39:
124–131.
Stevenson GW, Mercer H, Cormier J, Dunbar C, Benoit L, Adams C
et al. (2011). Monosodium iodoacetate-induced osteoarthritis
produces pain-depressed wheel running in rats: implications for
preclinical behavioral assessment of chronic pain. Pharmacol
Biochem Behav 98: 35–42.
Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K et al.
(2000). Activating transcription factor 3 (ATF3) induction by
axotomy in sensory and motoneurons: a novel neuronal marker of
nerve injury. Mol Cell Neurosci 15: 170–182.
Rat model of bortezomib-induced painful neuropathy BJP
British Journal of Pharmacology (2017) •• ••–•• 13
Voorhees PM, Dees EC, O’Neil B, Orlowski RZ (2003). The proteasome
as a target for cancer therapy. Clin Cancer Res 9: 6316–6325.
Wodarski R, Delaney A, Ultenius C, Morland R, Andrews N, Baastrup
C et al. (2016). Cross-centre replication of suppressed burrowing
behaviour as an ethologically relevant pain outcome measure in the
rat. Pain 157: 2350–2365.
Yamamoto S, Kawashiri T, Higuchi H, Tsutsumi K, Ushio S, Kaname T
et al. (2015). Behavioral and pharmacological characteristics of
bortezomib-induced peripheral neuropathy in rats. J Pharmacol Sci
129: 43–50.
Zheng H, XiaoWH, Bennett GJ (2012). Mitotoxicity and bortezomib-
induced chronic painful peripheral neuropathy. Exp Neurol 238:
225–234.
Zimmerman M (1983). Ethical guidelines for investigations of
experimental pain in conscious animals. Pain 16: 109–110.
BJP N A Duggett and S J L Flatters
14 British Journal of Pharmacology (2017) •• ••–••
